Fuyi Li

Dr Fuyi Li

Group Leader, Computational Systems Oncology

South Australian Immunogenomics Cancer Institute

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.


Dr Fuyi Li is the Group Leader of Artificial Intelligence for Biological Innovation (ABI Lab) in SAiGENCI. His lab focuses on developing Artificial Intelligence and Machine Learning approaches for cancer research. Dr Li finished his PhD in 2020 at Monash University under the supervision of Professor Jiangning Song and Professor Trevor Lithgow. He then joined the laboratory of Professor Lachlan Coin as a bioinformatics research fellow (Level B) at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne. With a strong background in machine learning and a profound understanding of bioinformatics, Dr Li has garnered recognition for his pioneering work in developing advanced data-driven bioinformatics algorithms and tools. His primary focus lies in tackling intricate biological challenges by harnessing the power of these innovative computational approaches. Dr Li's research interests are at the forefront of the rapidly evolving field of bioinformatics. His work centres on the development and application of cutting-edge machine-learning techniques to interpret vast and diverse biological datasets. These datasets encompass a wide spectrum of biological information, ranging from a wide range of biomolecules data, omics data and histopathology image data. He has developed over 40 bioinformatics software/webservers, and these tools have been used/downloaded in >80 countries, processing >1,200,000 calculation jobs.

I am motivated to investigate, develop, and deploy cutting-edge computational methodologies to better understand and address a range of open and challenging problems in bioinformatics. One of my key contributions is developing AI-driven approaches to study gene expression regulation. This program yielded 35 published bioinformatics approaches (1st-, co-1st, and corresponding author) that enhanced prediction and analysis of gene regulation across genomics, transcriptomics, and proteomics, covering genomic elements annotation to Biomacromolecular Covalent Modification prediction, including DNA modifications, RNA post- transcriptomic modifications, and protein post-translational modifications (PTMs). Among these, 12 papers were Clarivate Highly Cited and 2 were Hot Papers. The research cited and used my tools are from countries including the US, UK, Japan, China, etc., showing the global impacts.

My developed tools have enhanced both academic and industrial pursuits, particularly in refining biomarker identification. For instance:

- Procleave [PMID: 32413515] (1st author, FWCI 4.40, 88 citations, >60,000 job submissions) has impacted many fields including structural biology, microbiology, agriculture, and industry field. (i) Procleave identified cleavage sites for proteins linked to neurodegenerative diseases, such as TMEM106B, enhancing understanding of TMEM106B’s role in amyloid fibril formation and contributing to potential therapeutic targets exploration for these disorders [PMID: 35247328, Cell, research from the US]. (ii) In microbiology, Procleave predicted the Esp743 cleavage site on the Enterococcal surface protein, influencing biofilm formation and antimicrobial resistance studies [PMID: 36103556, PLOS Pathogens, research from the US]. (iii) In agricultural biotechnology, Procleave predicted the cleavage site for Mpf2Ba1 protein activation, crucial for forming pores in insect cells. This enhances Mpf2Ba1’s effectiveness against the western corn rootworm, improving pest control and crop protection [PMID: 37443175, Nat Commun., research from the UK]. (iv) Procleave also impacted neurological research by predicting caspase-3 cleavage sites in Collectin-12, informed studies on brain immunity and neurodegenerative diseases’ phagocytic activity [PMID: 36906641, Cell Death Dis., research from Sweden]. Moreover, (v) a US company was satisfied with Procleave’s capabilities and purchased a 1-year commercial license for two protease-specific models. This transaction underscores Procleave’s commercial viability and potential to impact novel therapeutic development.

- My other tools have also had broad impacts, i.e., DeepCleave [PMID: 31566664, Bioinformatics] (1st author, FWCI 8.47, ESI top 1%, 116 citations, > 48,000 job submissions) impacted proteomics, enhanced understanding of protein degradation linked to O-GlcNAc [PMID: 35705054, Cell Reports], and supported CD95L studies, a protein involved apoptosis signalling, aiding in identifying novel regulatory mechanisms [PMID: 36694998]. GlycoMine [PMID: 25568279, Bioinformatics] (1st author, FWCI 4.61, 189 citations, >76,000 job submissions) was used in the human surfaceome study to predict glycosylation sites, distinguishing surface from intracellular proteins, and aiding targeted drug development [PMID: 30373828, PNAS]. A Swiss company was satisfied with ProsperousPlus [PMID: 37874948] (1st author)'s capabilities and showed their great interest in purchasing the commercial license, currently negotiating.

  • Current Higher Degree by Research Supervision (University of Adelaide)

    Date Role Research Topic Program Degree Type Student Load Student Name
    2025 Co-Supervisor To explore the possibility of using Artificial Intelligence models to answer questions about the immune system's fight against cancer Doctor of Philosophy Doctorate Full Time Mr Galen Raphael Pereira
    2025 Principal Supervisor Integrating multi-omics data to identify novel biomarkers for improved disease diagnosis and prognosis Doctor of Philosophy Doctorate Full Time Miss Anxuan Han
  • Editorial Boards

    Date Role Editorial Board Name Institution Country
    2022 - ongoing Board Member BMC Bioinformatics Springer Nature United States
    2020 - ongoing Board Member Frontiers in Bioinformatics Frontiers United States
  • Position: Group Leader, Computational Systems Oncology
  • Phone: 83133424
  • Email: fuyi.li@adelaide.edu.au
  • Campus: West End Health Precinct
  • Building: AHMS - Adelaide Health and Medical Sciences, floor Ninth Floor
  • Room: 9055
  • Org Unit: South Australian Immunogenomics Cancer Institute

Connect With Me
External Profiles